From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Cancer type | Patients | Trial, ID | Follow-up | Outcomes | Reference |
---|---|---|---|---|---|
Malignant pleural mesothelioma | Previously treated | Phase 2 NCT03048474 | > 12 months | ORR, 38% Median PFS, 6.2 months 6-month PFS rate, 50% Median OS, not reached 12-month OS rate, 64% Grade 3-4 AEs, 38% | Disselhorst et al 2019 |
Malignant pleural mesothelioma | Previously treated | Phase 2 NCT02716272 | > 16 months | ORR, 28% Median PFS, 5.6 months 12-month PFS rate, 23% Median OS rate, 15.9 months 12-month OS rate, 58% Grade 3-4 AEs, 26% | Scherpereel et al 2019 |
Unresectable Sarcoma | Previously treated | Phase 2 NCT02500797 | > 12 months | Confirmed response, 16% Median PFS, 4.1 months Median OS, 14.3 months Grade 3-4 AEs, 14% | D’Angelo et al 2018 |
Esophagogastric cancer | Previously treated | Phase 1/2 NCT01928394 | Â | Investigator assessed ORR, 24% Median PFS, 1.4 months 12-month PFS rate, 17% Median OS, 6.9 months 18-month OS rate, 28% Grade 3-4 AEs, 35% | Janjigian et al 2018 |
Prostate cancer | Previously treated, AR-V7 positive | Phase 2 NCT02601014 | ≥ 1.9 months | ORR, 25% Median PFS,3.7 months Median OS, 8.2 months Grade 3-4 AEs, 46% | Boudadi et al 2018 |